Overview
Exploring the Future of IBD Care: The Role of JAK Inhibitors
IBD Expert Perspectives
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Advance your understanding on new and innovative approaches to care, focusing on the role of JAK Inhibitors in the treatment of IBD. Leading US gastroenterology faculty recently gave a series of lectures across the country on the latest research and treatment regimen recommendations in IBD to enhance optimal health outcomes.
Thomas Ullman, MD, Chief of the Division of Gastroenterology at Montefiore Medical Center/Albert Einstein College of Medicine in new York City, will review and discuss the latest research in this recorded live Visiting Professorship which includes a downloadable resource.
This activity is intended for gastroenterologists, and other allied health care professionals interested in the JAK/STAT signaling pathway and applications to treatment of IBD.
Advance your understanding on new and innovative approaches to care, focusing on the role of JAK Inhibitors in the treatment of IBD. This recorded live Visiting Professorship includes downloadable slides from the visiting lecture series.
Upon completion of this activity, participants will be able to:
• Discuss the role of the JAK/STAT signaling pathway in the inflammation and disease progression of IBD
• Compare and contrast the cytokine pathways targeted by JAK inhibitors under investigation for IBD
• Interpret the clinical trial efficacy and safety data of available and emerging JAK inhibitors investigated for Crohn’s disease and ulcerative colitis
• Identify IBD patients who may require a change in therapy due to lack or loss of response
• Discuss the role of the JAK/STAT signaling pathway in the inflammation and disease progression of IBD
• Compare and contrast the cytokine pathways targeted by JAK inhibitors under investigation for IBD
• Interpret the clinical trial efficacy and safety data of available and emerging JAK inhibitors investigated for Crohn’s disease and ulcerative colitis
• Identify IBD patients who may require a change in therapy due to lack or loss of response
Sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Gilead Sciences, Inc.
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
Thomas Ullman, MD
Chief, Division of Gastroenterology
Montefiore Medical Center/Albert Einstein College of Medicine
Bronx, NY
Chief, Division of Gastroenterology
Montefiore Medical Center/Albert Einstein College of Medicine
Bronx, NY
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
The following financial relationships have been provided by Faculty/Planning Committee Members:
Planning Committee
Bruce Sands, MD, MS
Consulting: AbbVie, Allergan, Amgen, Arena Pharmaceuticals, AstraZeneca, Boehringer-Ingelheim, Celgene, Celltrion Healthcare, Ferring, Gilead Sciences, Inc., F. Hoffmann-La Roche AG, Ironwood Pharmaceuticals, Janssen Pharmaceuticals, Inc., Lilly, Otsuka, Prometheus Laboratories Inc., Salix, Shire, Takeda, Theravance Biopharma R&D, Inc., Pfizer, Inc.
Grant/Research Support (Institution): Celgene
Honoraria: Takeda
Faculty
Thomas Ullman, MD
Advisory Board Member: Pfizer, Inc.
Honorarium Recipient: Janssen Pharmaceuticals, Inc.
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Tofacitinib, peficitinib, filgotinib, upadacitinib, and other JAK inhibitors under investigation for IBD as well as zoster vaccine recombinant if younger than 50.
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, complete the posttest and evaluation. To receive credit, 70% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Melissa Stradal at 773-714-0705 x160
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Academy for Continued Healthcare Learning designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.